Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Counsyl | RCV000169156 | SCV000220383 | likely pathogenic | Glycogen storage disease type III | 2014-06-05 | criteria provided, single submitter | literature only | |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV000169156 | SCV001554545 | likely pathogenic | Glycogen storage disease type III | 2021-03-31 | criteria provided, single submitter | clinical testing | Variant summary: AGL c.94C>T (p.Gln32X) results in a premature termination codon, predicted to cause a truncation of the encoded protein or absence of the protein due to nonsense mediated decay, which are commonly known mechanisms for disease. The variant allele was found at a frequency of 4e-06 in 251228 control chromosomes (gnomAD). c.94C>T has been reported in the literature in at least an individual affected with Glycogen Storage Disease Type III (example: Shaiu_2000). To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. No clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014. Based on the evidence outlined above, the variant was classified as likely pathogenic. |
Labcorp Genetics |
RCV000169156 | SCV001584150 | pathogenic | Glycogen storage disease type III | 2025-01-31 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Gln32*) in the AGL gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in AGL are known to be pathogenic (PMID: 19299494). This variant is present in population databases (rs786204489, gnomAD 0.008%). This premature translational stop signal has been observed in individual(s) with glycogen storage disease III (PMID: 10655153). ClinVar contains an entry for this variant (Variation ID: 188818). For these reasons, this variant has been classified as Pathogenic. |
Genome- |
RCV000169156 | SCV002055460 | pathogenic | Glycogen storage disease type III | 2021-07-15 | criteria provided, single submitter | clinical testing | |
Baylor Genetics | RCV000169156 | SCV004211013 | pathogenic | Glycogen storage disease type III | 2023-09-14 | criteria provided, single submitter | clinical testing |